CD8A and neoplasm: Our previous study using the squamous cell carcinoma model revealed that C‐REV treatment was able efficiently to recruit the CD8 T‐cells with a low expression of PD‐1 to the tumor tissues, suggesting that C‐REV has the potential to overcome the limitations posed by the PDL‐1 enriched immunosuppressive TME characteristic of aggressive solid malignancies [19].